Investor Relations

Overview

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. Our first commercial product, Jakafi® (ruxolitinib), is approved in the United States for patients with intermediate or high-risk myelofibrosis and for patients with polycythemia vera who have had an inadequate response to or are intolerant to hydroxyurea. We have a diverse and growing portfolio of product candidates, including both small and large molecules.

Events & Presentations

Upcoming
More events are coming soon.
Prior

November 28, 2018 3:30 PM EST
Evercore ISI HEALTHCONx

October 30, 2018 8:00 AM EDT
Q3 2018 Incyte Corporation Earnings Conference Call

September 13, 2018 10:00 AM EDT
Morgan Stanley 16th Annual Global Healthcare Conference

SEC Filings

Filing date Description Filing Group View

Statement of changes in beneficial ownership of securities

3,4,5

Statement of changes in beneficial ownership of securities

3,4,5

Statement of changes in beneficial ownership of securities

3,4,5

Investor Contacts

Michael Booth D.Phil
Vice President, Investor Relations
Phone: 302.498.5914
E-mail: mbooth@incyte.com

Lauren Kwiecinski
Senior Director, Investor Relations
Phone: 302.498.6141
E-mail: lkwiecinski@incyte.com

Computershare
P.O. Box 43078
Providence, RI 02940-3078 Phone: 877.272.1536